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Abstract
Purpose: Notch signaling dysregulation is implicated in the development of pancreatic adenocarcinoma (PDAC). Tarextumab is a fully human IgG2 antibody that
inhibits Notch2/3 receptors.

Presentation: Gastrointestinal Cancers Symposium, San Francisco, January 2017.
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original
work is properly cited.
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Patients and Methods: Aphase 2, randomized, placebo‐controlled, multicenter trial
evaluated the activity of tarextumab in combination with nab‐paclitaxel and gemcitabine in patients with metastatic PDAC. Patients were stratified based on ECOG
performance score and Ca 19‐9 level and randomized 1:1 to nab‐paclitaxel, gemcitabine with either tarextumab or placebo. Based on preclinical and phase Ib results
suggesting a positive correlation between Notch3 gene expression and tarextumab
anti‐tumor activity, patients were also divided into subgroups of low, intermediate,
and high Notch3 gene expression. Primary endpoint was overall survival (OS) in all
and in patients with the three Notch3 gene expression subgroups (≥25th, ≥50% and
≥75% percentiles); secondary end points included progression‐free survival (PFS),
12‐month OS, overall response rate (ORR), and safety and biomarker investigation.
Results: Median OS was 6.4 months in the tarextumab group vs 7.9 months in the
placebo group (HR = 1.34 [95% CI = 0.95, 1.89], P = .0985). No difference observed
in OS in the Notch3 gene expression subgroups. PFS in the tarextumab‐treated group
(3.7 months) was significantly shorter compared with the placebo group (5.5 months)
(hazard ratio was 1.43 [95% CI = 1.01, 2.01]; P = .04). Grade 3 diarrhea and thrombocytopenia were more common in the tarextumab group.
Conclusions: The addition of tarextumab to nab‐paclitaxel and gemcitabine did not
improve OS, PFS, or ORR in first‐line metastatic PDAC, and PFS was specifically
statistically worse in the tarextumab‐treated patients.
Clinical trial registry no: NCT01647828.
KEYWORDS
cancer stem cell, gemcitabine, nab‐paclitaxel, Notch 2/3 receptor inhibitor, Pancreatic cancer, tarextumab
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IN T RO D U C T ION

Patients with pancreatic ductal adenocarcinoma (PDAC) face
a challenging prognosis. More than half of those at diagnosis
have stage IV disease for which the 5‐year overall survival is
3%.1 Current combination cytotoxic therapies for metastatic
PDAC have shown real but modest overall survival impact.2,3
A potential explanation for either de novo or acquired treatment resistance is the presence of cancer stem cells (CSCs),
cells that possess the capacity for self‐renewal, differentiation
into multiple lineages, and the ability to proliferate extensively.4 CSCs have been shown to be more resistant to chemotherapy and radiotherapy than remaining epithelial malignant
cells, persisting after therapy to drive tumor growth.5,6 The
abnormal expression of the Notch pathway, a key regulator
of PDAC CSCs, has been linked to disease progression and
chemotherapy resistance in metastatic PDAC.7-11
Tarextumab (OMP‐59R5) is a fully human IgG2 antibody against the Notch2 and Notch3 receptors.12 Preclinical
studies using pancreatic xenograft models have found that
treatment with the combination of tarextumab, gemcitabine,
and nab‐paclitaxel induced tumor regression, decreased

CSC frequency, and delayed tumor progression compared to
treatment with cytotoxic therapy alone.12 Tarextumab also
downregulated Rg5, a marker of developing pericytes, and
facilitated pericyte recruitment to endothelial cells. Loss of
Rg5 has been reported to reduce tumor hypoxia and to normalize vasculature.13 Consequently, tarextumab may enhance
chemotherapy sensitivity by lowering CSC frequency and reducing tumor hypoxia. Higher Notch3 gene expression levels in these pancreatic tumor models were also found to be
associated with increased sensitivity to the combination of
tarextumab and gemcitabine. Based on the preclinical data,
our hypothesis was that PDAC patients with higher levels
of Notch3 gene expression in tumor cells would have an enhanced potential for therapeutic benefit from the addition of
tarextumab to standard therapy.
In a phase Ib study of N = 38 patients with previously
untreated metastatic PDAC, tarextumab was evaluated in
combination with nab‐paclitaxel and gemcitabine. The recommended phase 2 dose (RP2D) was determined to be 15 mg/
kg with standard doses of the cytotoxic agents. Diarrhea,
fatigue, and anemia were the most common tarextumab‐related toxicities, and the events were mostly Grade 1 or 2.
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The overall response rate (CR + PR) was 29%.14 The median
PFS and OS were 5.6 and 11.6 months, respectively. Patients
with high expression of Notch3 were noted to have a PFS
of 6.6 months and OS of 14.6 months. These results were
deemed to compare favorably to reported PFS of 5.5 months
and OS of 8.5 months in patients treated with gemcitabine
and nab‐paclitaxel.3
Given the encouraging preclinical data, tolerable safety
profile and the favorable PFS and OS results in the phase Ib
study, a randomized phase II study comparing gemcitabine,
nab‐paclitaxel with either tarextumab or placebo was initiated in patients with previously untreated metastatic PDAC.

2
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PAT IE N TS A N D ME T HOD S

|

Study design and participants

This was a prospective, multicenter, randomized, double‐
blinded, placebo‐controlled phase II study in patients with
untreated metastatic PDAC. Patients were randomized in 1:1
ratio to receive either nab‐paclitaxel, gemcitabine and placebo or nab‐paclitaxel, gemcitabine and tarextumab (Figure
1). Patients were divided into subsets based on Notch3 gene
expression levels: Notch3 ≥ 25th percentile; Notch3 ≥ 50th
percentile; Notch3 ≥ 75th percentile and all patients irrespective of Notch3 expression levels.
The primary endpoint of the study was overall survival
(OS). Secondary endpoints included progression‐free survival (PFS), overall response rate (ORR), duration of response (DOR), and CA19‐9 response.
Exploratory endpoints not reported herein included expression levels of epidermal growth factor receptor (EGFR),
placental growth factor (PLGF), epithelial neutrophil‐activating peptide (ENA 78), and other Notch‐related genes

FIGURE 1

in the serum obtained at baseline and disease progression.
Circulating tumor cells (CTCs), microRNAs, and circulating
endothelial cells were also evaluated and will be reported
separately.
Tumor assessments were assessed by RECIST version
1.1 every 8 weeks using computed tomography or magnetic
resonance imaging. Adverse events were graded using the
National Cancer Institute Common Terminology Criteria for
Adverse Events (CTCAE), version 4.02.15
Individuals (age > 18 years) with newly diagnosed, pathologically confirmed stage IV PDAC were enrolled. Eligibility
criteria also included the presence of measurable disease
according to RECIST version 1.1 and Eastern Cooperative
Oncology Group (ECOG) performance status of 0 or 1. In
additions, patients must have had formalin‐fixed, paraffin‐
embedded (FFPE) tumor tissue from metastatic sites, either
archived or fresh core needle biopsied for Notch3 analysis at
study entry.
Patients were required to have adequate organ function as defined by the following factors: absolute neutrophil count ≥ 1.5 × 109/L, hemoglobin ≥ 9.0 g/dL,
platelets > 100 × 109/L (have not received hematopoietic growth factors, transfusion of blood and blood products ≥ 1 week prior to meeting the eligibility criteria),
serum creatinine ≤ 1.5 mg/dL or calculated creatinine
clearance ≥ 60 mL/min using the Cockcroft and Gault
formula, bilirubin ≤ 1.5 × upper limit of normal (ULN),
alanine aminotransferase (ALT) ≤ 3 × ULN, aspartate aminotransferase (AST) ≤ 3 × ULN), PT/INR ≤ 1.5 × ULN,
aPTT ≤ 1.5 × ULN.
Patients were excluded for the following reasons: neuroendocrine tumors of the pancreas, brain metastases, prior
therapy for stage IV PDAC, known human immunodeficiency virus (HIV) infection, and major surgery <4 weeks

CONSORT diagram. ITT, intent to treat; nab‐p, nab‐paclitaxel; gem, gemcitabine
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prior to the first treatment. In addition, patients with serious
or unstable concomitant systemic disorder incompatible with
the study such as active infection, arterial thrombosis, and
symptomatic pulmonary embolism were ineligible as were
patients with any disorder that would significantly compromise protocol compliance.

2.2

|

Procedures

Nab‐paclitaxel 125 mg/m2 and gemcitabine 1000 mg/m2
were administered on Days 1, 8, and 15 of every 28‐day
cycle. Tarextumab or placebo was dosed at 15 mg/kg and
administered on Days 1 and 15 of every 28‐day cycle. On
days when tarextumab, nab‐paclitaxel and gemcitabine were
given, tarextumab was administered first, then nab‐paclitaxel
followed by gemcitabine. All agents were dosed until either
disease progression or limiting toxicity occurred.

2.3

|

Statistical analyses

Overall survival was the primary efficacy endpoint of this
study and was defined as the time from randomization until
death. The hazard in the control arm was 0.09 (median
8 months) and hazard in the tarextumab arm 0.07 (median
10 months). No treatment cross‐over was permitted in the
study. The Kaplan‐Meier method was used to estimate both
the survival curves and the median survival time. The 95%
confidence intervals for median survival times and P‐value
for treatment effect were generated using a stratified Cox
proportional hazards model.
Final analysis of the study was planned to take place
at the point when 104 progression events had occurred or
10 months after the completion of enrollment, whichever occurred first. This would ensure the study had 75% power to
detect a hazard ratio of 0.67 (improvement in median PFS
from 5.5 months to 8.2 months) and 80% power to detect a
hazard ratio of 0.65 (improvement in median PFS from 5.5
to 8.5 months) in the intention‐to‐treat (ITT) population with
an associated total one‐sided type 1 error of 0.10. The data
cutoff for the final analysis of survival was 6 months after the
data cutoff for the final analysis of PFS or when 104 deaths
have been observed, whichever occurred first.
Data were combined from all participating study sites for
the analyses. All statistical testing was two‐sided and was
performed at the 0.05 significance level. For continuous variables, descriptive statistics included the mean, SD, median,
minimum, maximum, and the number of non‐missing values. For categorical variables, descriptive statistics included
counts and percentages per category.
Notch3 gene expression analyses were conducted as
follows; Notch3 gene expression correlated with efficacy
in preclincial models. Ten primary patient derived pancreas cancer tumor xenografts were tested for efficacy in

|
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response to gemcitabine and tarextumab. Significant correlation was found between the levels of tumor‐derived
Notch3 and the efficacy of tarextumab. Responder tumors
had higher levels of Notch3 compared to nonresponders
when treated with the combination of chemotherapy and
the antibody. Subsequently data from the phase Ib clinical
trial evaluated 32 patient samples from 40 patients enrolled
in 6 dose levels of tarextumab (ranging from 2.5 to 15 mg/
kg) with an 80% success rate for Notch3 gene expression
adjudication. A trend was observed for the higher levels of
Notch3 and increased time to tumor progression. Based on
these collective preclinical and clinical data Notch3 gene
expression subgroups (≥25th, ≥50% and ≥75% percentiles)
were chosen to best differentiate outcome for the randomized phase II trial.

|

2.4

Study oversight

The study was conducted in accordance with the Guideline
for Good Clinical Practice, the ethical principles of the
Declaration of Helsinki, and was approved by the institutional review board at every site. All patients provided written informed consent before enrollment.

3
3.1

|

RESULTS

|

Patients

A pre‐planned interim efficacy and safety analysis was conducted by an independent Data and Safety Monitoring Board
(DSMB) on data from N = 172 patients treated by January
2016 data cutoff date. From a safety standpoint, the DSMB
identified no unexpected safety signals but noted worse RR
and PFS in the tarextumab treatment group and a strong trend
toward lack of OS benefit in the tarextumab treatment group,
irrespective of Notch3 expression levels. The study was subsequently terminated in March 2016 by the sponsor due to
futility.
One hundred and seventy‐seven patients were enrolled
in the study in 25 centers throughout the United States from
July 2014 to March 2016 (Table 1). Fifty‐nine per cent
were male, the median age was 66 years (range 34‐88) and
the majority of patients were white. Eighty‐nine patients
were assigned to the tarextumab arm and N = 88 to the
placebo arm.
The median duration of treatment was 2.6 months (range:
0, 17.3) and 4.2 months (range: 0, 15.9) for patients in the tarextumab treatment group and the placebo group, respectively.
The patients treated with tarextumab received a median of
6.0 doses (range: 1, 37). The patients in the placebo group
received a median of 9.0 doses (range: 1, 35). Two placebo
patients were lost to follow‐up and two tarextumab‐treated
patients withdrew consent.
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Tarextumab (n = 89)

Placebo (n = 88)

66 (34‐88)

66 (40‐82)

Male

50 (56%)

54 (61%)

104 (59%)

Female

39 (44%)

34 (39%)

73 (41%)

0

34 (38%)

34 (39%)

68 (38%)

1

55 (62%)

54 (61%)

109 (62%)

Median age, years
(range)

Total (n = 177)
66 (34‐88)

TABLE 1

characteristics

Patient baseline

Sex, n (%)

ECOG score, n (%)

CA 19‐9 Levels
0 to ULN

19 (21%)

18 (20%)

37 (21%)

>ULN to 59xULN

24 (27%)

26 (30%)

50 (28%)

≥59xULN

46 (52%)

44 (50%)

90 (51%)

Primary pancreatic tumor location, n (%)a
Head

39 (44%)

37 (42%)

76 (43%)

Body

34 (38%)

32 (36%)

66 (37%)

Tail

29 (33%)

32 (36%)

61 (35%)

Other

10 (11%)

9 (10%)

19 (11%)

Current site(s) of metastasis, n (%)a
Pancreas

86 (97%)

83 (94%)

169 (96%)

Liver

76 (85%)

78 (89%)

154 (87%)

Lungs

39 (44%)

31 (35%)

70 (40%)

Lymph nodes

34 (38%)

45 (51%)

79 (45%)

Other

23 (26%)

24 (27%)

47 (27%)

Kidney

3 (3%)

3 (3%)

6 (3%)

Bone

5 (6%)

5 (6%)

10 (6%)

Number of metastatic sites, n (%)
1

1 (1%)

1 (1%)

2 (1%)

2

28 (32%)

27 (31%)

55 (31%)

≥3

60 (67%)

59 (67%)

119 (67%)

Yes

6 (7%)

6 (7%)

12 (7%)

No

83 (93%)

82 (93%)

165 (93%)

Prior surgery, n (%)

Prior radiotherapy, n (%)
Yes

2 (2%)

1 (1%)

3 (2%)

No

87 (98%)

87 (99%)

174 (98%)

Prior systemic therapy, n (%)b
Yes

1 (1%)

2 (2%)

3 (2%)

No

88 (99%)

86 (98%)

174 (98%)

a

Patients may be included in more than one site of disease. Percentage may add up to more than 100%.
These patients received prior systemic therapy as adjuvant therapy.

b

3.2
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Efficacy

The median OS was 6.4 months (95% CI = 4.17, 8.2) in the
tarextumab group compared with 7.9 months (95% CI = 6.18,
10.52) in the placebo group (Figure 2A). No statistically significant difference was observed in OS in the tarextumab treatment

group compared with the placebo group (HR = 1.34 [95%
CI = 0.95, 1.89], P = .09). No statistically significant difference
was observed in OS in patients with Notch3 ≥ 25th percentile,
Notch3 ≥ 50th percentile, or Notch3 ≥ 75th percentile (Figure 3).
The median PFS was 3.7 months (95% CI = 1.94, 4.21) in
the tarextumab group and 5.5 months (95% CI = 3.72, 5.79)

IAN HU et al
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F I G U R E 2 (A) Overall survival
and (B) Progression‐free survival in the
intent‐to‐treat population. Red, tarextumab
with gemcitabine and nab‐paclitaxel; black,
placebo with gemcitabine and nab‐paclitaxel

F I G U R E 3 Kaplan‐Meier analysis of overall survival in the intent‐to‐treat population divided by percentile. (A) OS for patients with ≥25th
percentile Notch3 expression, (B) OS for patients with ≥50th percentile Notch3 expression, (C) OS for patients with ≥75th percentile Notch3
expression. Red, tarextumab with gemcitabine and nab‐paclitaxel; black, placebo with gemcitabine and nab‐paclitaxel
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Responsea

Tarextumab + nab‐paclitaxel + gemcitabine (n = 89)

Placebo + nab‐paclitaxel + gemcitabine (n = 88)

Overall response rate

18 (20%)

28 (32%)

Partial response

18 (20%)

28 (32%)

Stable disease

31 (35%)

36 (41%)

Progression of disease
(POD)

21 (24%)

6 (7%)

Not Evaluable

—

1 (1%)

Clinical POD (no follow up imaging)

19 (21%)

TABLE 2

Treatment response

17 (19%)

a

Per RECIST v1.1

for the placebo group (Figure 2B). The PFS in the tarextumab
treatment group was significantly shorter compared with the
placebo group (HR 1.43 [95% CI = 1.01, 2.01]; P = .04). No
statistically significant difference was observed in PFS in patients with Notch3 ≥ 25th percentile, Notch3 ≥ 50th percentile, or Notch3 ≥ 75th percentile.
There was no significant difference in ORR (P = .087)
between the placebo‐treated group (31.8%; 95% CI = 22.3%,
42.6%) compared with the tarextumab‐treated group (20.2%;
95% CI = 12.4%, 30.1%) (Table 2). There was no significant
difference in ORR between the Notch3 subgroups and placebo treatment groups.
The median duration of response (DOR) was 3.7 months
(95% CI = 1.64, 5.52) in the tarextumab group and 3.6 months
(95% CI = 2.14, 5.59) in the placebo group. No statistically
significant difference was observed in the DOR between the
two groups (P = .99).
CA19‐9 response was defined as a decrease of 50% or
more in baseline CA19‐9 at any time post‐baseline. There
was no statistically significant difference (P = .15) in response between the placebo group (47.7%) and the tarextumab‐treated group (37.1%).

3.3
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Safety

Treatment‐emergent adverse events (TEAEs) are summarized
in Table 3. TEAEs were reported in 93% of the tarextumab
group and 80% of the placebo group. There were no statistically significant differences in the rate of adverse events between the groups. Diarrhea (72% vs 40%), nausea (41% vs
31%), and thrombocytopenia (49% vs 25%) were noted to
occur more frequently in the tarextumab treatment group.
Fifty‐one (60%) patients in the placebo and N = 58 (66.7%)
patients in the tarextumab group reported one or more serious
AEs (SAE). In the tarextumab group, 22 (25.3%) patients had
Grade 3 and 3 (3.4%) patients had Grade 4 SAE. Fourteen
(16.1%) SAEs in the tarextumab‐treated group and 16 (18.8%)
in the placebo‐treated group resulted in patient death; none of
these SAEs were considered related to study drug treatment.

TEAEs in 8 tarextumab‐treated patients resulted in treatment interruptions and 6 patients experienced tarextumab
dose reductions due to TEAEs. TEAEs led to treatment discontinuation in 7 patients. A total of 126 (73.3%) patients
died within 30 days of study discontinuation, 69 (79.3%)
TABLE 3

Treatment‐emergent adverse events related to
tarextumab with incidence of at least 10% by system organ class
Placebo (n = 85)

Tarextumab
(n = 87)

Diarrhea

34 (40%)

63 (72%)

Nausea

26 (31%)

36 (41%)

Vomiting

14 (16%)

19 (22%)

Fatigue

50 (59%)

45 (52%)

Fever

10 (12%)

8 (9%)

Thrombocytopenia

21 (25%)

43 (49%)

Anemia

22 (26%)

25 (29%)

Neutropenia

15 (18%)

8 (9%)

System organ class
Gastrointestinal disorders

General disorders

Hematologic disorders

Metabolism and nutrition disorders
Decreased appetite

11 (13%)

15 (17%)

Dehydration

10 (12%)

8 (9%)

8 (9%)

11 (13%)

Nervous system disorders
Dysgeusia

Respiratory, thoracic and mediastinal disorders
Epistaxis

1 (1%)

9 (10%)

Patients with Grade 3 or 4 TEAEs
Diarrhea

2 (2%)

15 (17%)

Nausea

1 (1%)

6 (7%)

Fatigue

9 (11%)

13 (15%)

Thrombocytopenia

6 (7%)

19 (22%)

Anemia

8 (9%)

14 (16%)

10 (12%)

3 (3%)

Neutropenia

IAN HU et al

tarextumab‐treated patients and 57 (67.1%) placebo‐treated
patients. None of the deaths were adjudicated as related to
tarextumab.
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D IS C U SSION

Strong preclinical evidence with patient‐derived xenograft
(PDX) pancreatic models and phase Ib trial data provided a
compelling rationale for the clinical evaluation of Notch signaling inhibition combined with gemcitabine and nab‐paclitaxel
therapy in a randomized phase 2 trial.12 Tarextumab treatment
in combination with gemcitabine in PDX models resulted in
decreased Notch2 and Notch3 expression, increased apoptotic
cell death, decreased tumor cell density, and increased vessel
perfusion and decreased hypoxia intratumorally.12 Mean gene
expression levels of Notch3 were noted to be significantly
higher in responders compared to nonresponders, suggesting
that higher Notch3 expression may be a useful biomarker of
sensitivity to tarextumab treatment.
In view of the encouraging preclinical findings, early
phase trials were initiated in metastatic PDAC and extensive
stage small cell lung cancer. Results from both phase Ib clinical trials were potentially promising, with reported response
rates of 84% and 74% in the small cell lung and pancreatic
cancer trials, respectively.14,16 Analysis of the phase Ib clinical trial in PDAC demonstrated a PFS of 5.6 months and OS
of 11.6 months in patients treated with tarextumab in combination with gemcitabine and nab‐paclitaxel. In the subgroup
of patients with high Notch3 expression, PFS and OS were
6.6 and 14.6 months, respectively.
However, both the small cell lung cancer and PDAC
randomized phase II clinical trials failed to meet their primary objective of a statistically significant improvement
in OS. In the trial reported herein in PDAC, the PFS for
the tarextumab treatment group was shorter compared to
the placebo group. Analysis of the Notch3 subgroups also
found no difference in PFS and OS between the subgroups.
To summarize, we found no benefit in adding tarextumab
to standard cytotoxic therapy in this randomized phase II
trial of patients with metastatic PDAC, with a statistically
significant decrease in median PFS and concerning negative trend in OS for some pre‐specified subgroups. It is
possible that some of the worse outcome was attributed to
higher toxicity in the tarextumab vs placebo‐treated patients resulting in a lower median treatment duration (2.6
vs 4 months) and lower median number of treatment doses
(6 vs 9 doses).
The discordances between the preclinical along with the
early clinical development (phase Ib trial) results and the
randomized phase II results are concerning and may be attributed to differences in xenograft development, the patient
population in the clinical trials, as well as the pleotropic
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nature of the Notch receptors and unrecognized contributions from the PDAC stroma. The human xenograft tumors
used for the preclinical heterotopic implant model were
obtained from stage III PDAC patients without metastases
whereas the clinical trial treated metastatic PDAC patients.
Compared to heterotopic models, orthotopic PDAC models,
where tumor cells are implanted directly into the pancreas,
retain a greater proportion of stromal components and develop locoregional and distant metastases.17,18 Consequently,
the preclinical results may have been more predictive of
outcome for a localized PDAC population. In the phase Ib
clinical trial, 11/38 patients (27.5%) patients had ≥3 metastatic sites and 14 (35.0%) patients had two metastatic sites.
In contrast, 67.2% of patients in the phase II clinical trial
had ≥3 metastatic sites and 31.1% had two metastatic sites.
Given the differences between the heterotopic PDX model
and patient population, it is difficult to ascertain what roles
Notch2 and Notch3 inhibition may play in promoting or inhibiting disease progression in a locoregional vs metastatic
setting. An orthotopic or genetically engineered mouse models may promote better understanding in the future.
Notch1 inhibition has also been reported to cause
an increase in liver metastases from neuroblastoma and
breast cancer cells and may support early angiogenesis
and growth of micrometastases within the liver.19 The preclinical studies noted that tarextumab treatment alone and
not combination therapy, decreased Notch1 intracellular
domain levels in the xenograft OMP‐PN17 PDAC tumor.
This randomized phase II clinical trial also found no
significant difference in PFS and OS between the low, intermediate, and high Notch3 subgroups. Further analyses of
the exploratory biomarkers, including Notch‐related genes,
CTCs, and circulating endothelial cells collected in this trial
are ongoing and may be informative.
The exact role of Notch signaling in PDAC remains an
area of significant debate, with some evidence supportive
of an oncogenic role while other results have been more
suggestive of its function as a tumor suppressor. Notch receptors and ligands have been found to be overexpressed in
human and mouse PDAC cells, and have been implicated
in the progression of pancreatic intraepithelial neoplasia
(PanIN) lesions.10,20-22 Reports have differed, however,
on which specific Notch receptor is central in the progression of PanIN and PDAC lesions, with results supporting
Notch1,23 Notch2,21 and Notch3.24 Alternatively, loss of
Notch1 in a KRAS‐driven PDAC mouse model resulted
in increased tumor incidence and progression, implicating
Notch signaling as a potential tumor suppressor.25
The discrete, collective, and relative contributions of
the individual Notch receptors to tumor development in
PDAC patients remain to be resolved. Further research
into individual Notch inhibitors and agonists may help
guide future clinical trials involving the Notch pathway
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and cytotoxic chemotherapy. To additionally note, a randomized phase II trial evaluating an anti‐Delta‐like ligand
4 (DLL4) targeted agent (demcizumab), which is an inhibitor of the Notch pathway or placebo, combined with
gemcitabine and nab‐paclitaxel observed no improvement
in the primary endpoint of PFS compared to standard chemotherapy and similarly there was no difference in overall
survival (HR 1.02).26 The collective data suggest that targeting the Notch pathway to date has little clinical utility
in PDAC.
To sum up, the addition of tarextumab to gemcitabine
and nab‐paclitaxel in untreated advanced PDAC did not improve outcomes over standard therapy, and specifically PFS
was statistically worse in the tarextumab‐treated group. This
trial provides significant insights into the importance of preclinical modeling in optimal and relevant model systems and
underscores the need for randomized evaluation of experimental agents.
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an anti‐Notch 2/3 inhibitor, in combination with gemcitabine
and nab‐paclitaxel in untreated advanced PDAC did not improve outcomes over standard therapy. PFS was statistically
worse in the tarextumab‐treated group.
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